Logo-ijhpm
Int J Health Policy Manag. 2023;12: 7621 | Published on: 2023 Aug 21. doi: 10.34172/ijhpm.2023.7621
PMID: 38618821        PMCID: PMC10590253

Original Article

Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis

Anju Murayama 1 * ORCID, Sae Kamamoto 2, Hiroaki Saito 3 ORCID, Erika Yamashita 2, Yosuke Suzuki 2, Tetsuya Tanimoto 4,2 ORCID, Piotr Ozieranski 5 ORCID, Akihiko Ozaki 6 ORCID

Cited by CrossRef:

1- Murayama A, Kugo H, Senoo Y. Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan. BMJ Open. 2024;14(6):e086396 [Crossref]
2- Murasawa H, Shin N, Miyata H, Saito C, Tanimoto T, Saito H, Hakariya H, Mintzes B, Ozaki A. Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships. JCO Oncol Pract. 2025; [Crossref]
3- Murayama A, Senoo Y. Financial conflicts of interest among authors of clinical practice guideline for headache disorders in Japan. BMC Med Ethics. 2024;25(1) [Crossref]
4- Shiga R, Nakagawasai S, Hashimoto E, Cho I, Saito H, Ozaki A, Tanimoto T, Ando S, Shimmura H, Saito M, Tabuchi T. An analysis of research grants allocated to researchers by the Smoking Science Research Foundation funded by Japan Tobacco Inc. in 2018. Tob Prev Cessation. 2024;10(July):1 [Crossref]
5- Murayama A, Higuchi K, Byreddy K, Hinari K, Senoo Y. Pharmaceutical company payments to Japanese breast cancer practice guideline authors. Clinical and Translational Dis. 2024;4(3) [Crossref]